Hypocalcemia has been observed in patients receiving WR-2721 IS-,2-(3-aminopropylamino)-, ethylphosphorothioic acid]. WR-2721 is a compound that, after being dephosphorylated, provides protection of normal tissues against radio-and chemotherapy. The hypocalcemic response was accompanied by a decrease in the plasma level of parathyroid hormone (PTH) and by hypomagnesemia. Our present studies in rats on the mechanism of the hypocalcemic effect of WR-2721 indicate that: (a) The phosphorylated and dephosphorylated form of WR-2721 induced an equal dose-dependent decrement in plasma calcium. (b) In intact rats a maximal hypocalcemic dose of WR-2721 reduced urinary cyclic AMP excretion from 70.5±63 to 38.2±3.1 pmol/ml glomerular filtration rate (GFR), a level comparable to that observed (35.9±5.2 pmol/ml GFR) in thyroparathyroidectomized (TPTX) rats. (c) WR-2721 given to TPTX rats did not significantly interfere with the calcemic effect of bovine PTH 1-34 infused at 2.5 IU/h. Likewise, the drug did not impair the PTH actions on the renal Ca and inorganic phosphate (Pi) handling, and on the urine cyclic AMP excretion. (d) In TPTX rats made normocalcemic by low Pi diet, the hypocalcemic effect of WR-2721 was only about 25% of that observed in intact animals. However, it was associated with increased urine Ca per milliliter GFR, indicating a PTH-independent inhibitory effect on tubular Ca reabsorption. (e) In WR-2721-treated intact rats, prevention of hypomagnesemia by infusing magnesium chloride did not reduce hypocalcemia. In conclusion, the hypocalcemic effect of WR-2721 is not dependent upon the presence of a phosphate group in the molecule and is not causally related to hypomagnesemia. WR-2721 appears to be a unique hypocalcemic pharmacologic agent with strong inhibitory activity on PTH secretion and additional PTH-independent action on renal Ca reabsorption.
Introduction
The clinical expressions of primary hyperparathyroidism are various, and in some cases removal ofthe abnormal parathyroid gland is not the best therapeutic option (1) . As a substitute for surgery, the medical management ofprimary hyperparathyroidism would be facilitated if a rapid and efficient inhibition of parathyroid hormone (PTH)' secretion could be achieved by the 1 . Abbreviations used in this paper: GFR, glomerular filtration rate; Pi, inorganic phosphate; PTH, parathyroid hormone; TPTX, thyroparathyroidectomized.
use of a specific pharmacologic agent. So far, potential inhibitors ofPTH secretion, such as receptor antagonists ofeither histamine or f3-adrenergic catecholamines, have not proved to be effective in lowering consistently the plasma calcium level in patients with primary hyperparathyroidism (1) (2) (3) (4) (5) (6) .
Recently, a new hypocalcemic agent, WR-272 1, which may become a useful drug in the treatment of hyperparathyroidism, was discovered (7) . WR-2721 is an organic phosphorothioate (S-,2-(3-aminopropylamino)-, ethylphosphorothioic acid) that provides selective protection ofnormal tissues against the toxicity of radiation and alkylating agents in animals, including human beings (8) . In a group of normocalcemic cancer patients, the drug induced a fall in calcemia by -0.4 mmol/liter within 3 h. This effect was associated with a decrease in the plasma level of PTH, suggesting that WR-272 1 inhibits the production or release of PTH (7) . This notion was sustained by in vitro experiments showing that the drug reduced the release of PTH from bovine parathyroid gland cell suspensions (7) .
These data suggest that the major effect of WR-272 1 on the plasma Ca level is due to an inhibition of PTH secretion. However, other mechanisms could contribute to the fall in calcemia.
Indeed, WR-272 1 contains a phosphate group that, either bound to or liberated from the molecule within the extra-and/or intracellular space (9-1 1), might play, if not a key, at least a partial role in the hypocalcemic response. Furthermore, evidence for a direct inhibition of PTH secretion does not exclude additional interference with the action ofthe hormone on its target organs. Likewise, the drug could still exert a PTH-independent hypocalcemic effect by affecting bone and/or kidney Ca fluxes. Finally, it has been reported (7) that the hypocalcemic effect of WR-272 1 is associated with a fall in plasma magnesium. Thus, a change in Mg metabolism could also interefere with Ca homeostasis.
These different possible mechanisms of action have been considered in the present work by studying the effect of WR-2721 in intact and thyroparathyroidectomized rats. The reported results sustain the concept that WR-272 1 exerts its hypocalcemic action mainly by inhibiting PTH secretion. However, an additional PTH-independent effect on the tubular reabsorption of Ca could contribute to the drug-induced hypocalcemia.
Methods

Animal preparation
Male Wistar rats weighing 180-200 g were used. During a 5-10-d period preceding the experiment, the animals were fed a semisynthetic diet (Kliba, Klingentalmuihle AG, Switzerland) containing either 1.1% Ca and 0.8% phosphorus (normal Pi diet) or 1.1% Ca and 0.2% phosphorus (low Pi diet). 10 IU of vitamin D3 dissolved in vegetable oil was added to the daily ration. Food was provided for the last time the evening preceding the experiment. Groups of animals were thyroparathyroidectomized (TPTX) at least 7 d before the study. Only animals displaying a calcemia equal to or below 1.88 mM (7.5 mg/100 ml) 48 h after the operation were considered as TPTX and kept in the study. They were supplemented with thyroxine 2 Mg/I00 g ofbody weight subcutaneously every other day.
Standard experiment
All experiments were started between 8 and 9 a.m. Conscious animals were put into restrictive cages that allowed tail vein injections, and blood sampling from a hindlimb vein. After a first blood sampling, the drug was injected intravenously at the dose of0.07 mmol/l00 g ofbody weight unless otherwise indicated. This dose was dissolved in 0. 4 In one series of experiments, the role of hypomagnesemia was evaluated. Groups of rats received subcutaneously either WR-2721 or its solvent. Then, a continuous intravenous infusion of a 0.15 M NaCl containing 10 mM MgCl2 was installed. Blood samples were taken just before and 2, 5, and 7 h after the drug administration.
Renal clearance studies
The general methodology of renal clearance measurement in conscious rats was described in an earlier article (12) . In the present study the experiments were started between 8 and 9 a.m. and lasted until 5-6 p.m.
A first dose of0. 4 MCi of [methoxy-3Hlinulin dissolved in isotonic saline was injected intravenously in a volume of0. 4 (Fig. 1 a) . The hypocalcemic effect was maintained for at least 6-8 h. A complete normalization of plasma Ca was observed 24 h after drug administration. In order to elucidate whether the phosphate group present in this form of the compound may contribute to the hypocalcemic effect, the dephosphorylated analogue was administered in the same experimental conditions. As depicted in Fig. 1 b, (Fig. 4) . The PTH-induced rise in plasma Ca was not significantly different between the two groups, and the fall in urine Ca excretion was even more pronounced in the WR-272 1-treated animals (Fig. 4) .
Hypocalcemic effect of WR-2721 in TPTX rats. In order to investigate whether WR-272 1 would exert a PTH-independent hypocalcemic effect, the phosphorylated and dephosphorylated forms of the drug were administered to TPTX rats fed a normal Ca (1.1%), normal Pi (0.8%) diet. The results ofthese experiments are presented in Table I and Fig. 5 , where they are compared to those obtained in intact rats studied in the same experimental conditions. Note that a spontaneous fall in calcemia was observed in untreated TPTX rats in contrast to the maintenance of a steady value in intact counterparts. However, in TPTX rats treated with either form of WR-272 1, the decrement in plasma Ca determined 6 h after the drug application was significantly greater than in the corresponding control group.
Nevertheless, in TPTX rats, the difference in the drop of calcemia observed at 6 h between the untreated and treated group corresponded only to -25% of that recorded in the intact animals. It was associated with a mild rise in phosphatemia in TPTX animals injected with the phosphorylated, but not with the de- sualized on the diagram relating urine to plasma Ca (Fig. 6) . In intact rats the marked decrease in plasma Ca was accompanied by an increase in urine Ca, a change consistent with an inhibition of PTH secretion. In TPTX rats, however, WR-2721 still reduced the tubular Ca reabsorption capacity, indicating an additional PTH-independent effect on the renal Ca handling. Interestingly, Relation between WR-2721 induced hypomagnesemia and hypocalcemia. As shown in Fig. 7 , the hypocalcemic effect of WR-272 1 was accompanied by a concomitant fall in the plasma Mg concentration. Prevention of hypomagnesemia by infusing magnesium chloride did not attenuate the hypocalcemic response to WR-2721.
Discussion
The availability of a pharmacological agent that has the property of inhibiting rapidly and selectively PTH secretion could contribute to the diagnosis and medical management of hyperparathyroidism. Such an inhibitor would also represent an invaluable tool in experimental and clinical investigations aimed at defining the role of PTH in various physiologic processes and disorders ofCa homeostasis. The organic phosphorothioate WR-272 1 appears to be a serious candidate for filling this pharmacologic gap.
Our present experiments in rats demonstrate that the hypocalcemic effect of WR-2721 is dose-dependent, reaching a nadir after 2-6 h, with complete recovery 24 h after drug administration. The hypocalcemic response to WR-2721 can be obtained with both the phosphorylated and dephosphorylated forms which were equipotent when administered in various doses. Such a comparative study indicates first that an increase in inorganic phosphate resulting from any extra-or/and intracellular dephosphorylation of the molecule (9-1 1) cannot play a role in the hypocalcemic effect. Secondly, it suggests that, like for its radioprotective effect (9- 1 1) , the dephosphorylation of the molecule may be necessary for eliciting the hypocalcemic action. Fig. 4 , the administered dose of PTH increased calcemia of TPTX-untreated animals to a value still below the level recorded in intact rats (Fig. 1 a) . In the same experiment, the urinary cyclic AMP excretion rose in response to PTH from 35.9±52 to 70.8±6.9 pmol/ml GFR, a value quite similar to that monitored (70.5±6.3) in the intact untreated rats (Fig. 3) . Finally, in a previous work (13) the same dose of PTH as that used in the present study was shown to normalize without overcorrecting the tubular Ca reabsorptive capacity of TPTX rats. Therefore, it appears unlikely that, in intact rats, WR-272 1 could significantly interfere with the renal effects of PTH when secreted in normal or high amounts. Whether WR-2721 could display such an inhibitory activity when the PTH secretion rate is low cannot be excluded from the present studies.
As to a possible PTH antagonistic action at the skeletal level, our experiments in TPTX rats only show that the PTH-induced rise in plasma Ca was not significantly reduced by WR-2721 treatment. Obviously, this finding does not allow excluding some interference of the drug with the bone Ca-mobilizing action of PTH, in that it could be explained, at least in part, by the unimpaired stimulation of the tubular Ca reabsorption.
Our experiments demonstrate that both the phosphorylated and dephosphorylated forms of WR-272 1 still exert a hypocalcemic influence in TPTX rats. This effect appears to be much smaller than that observed in intact rats. It is important to note that in the PTH-deprived state the plasma Ca level is unstable, decreasing as soon as the animals stop eating. Thus the fall in calcemia observed in WR-2721 treated TPTX rats appears to be quite impressive as compared to untreated intact counterparts. However, it becomes quite moderate when compared to control PTH-deprived animals (Fig. 5 , Table I ).
The hypocalcemic effect observed in TPTX rats could be considered as trivial if it were associated with a slight fall in calciuria. However, on the contrary, our experiments demonstrate that it occurs with a marked elevation in the urinary output of Ca. The plotting of the data on the diagram relating urine to plasma Ca allows assessment of the changes in the tubular Ca reabsorptive capacity (13) . Examination of Fig. 6 strongly suggests that WR-272 1 elicits a PTH-independent reduction in the tubular Ca reabsorptive capacity. Whether or not this renal effect accounts entirely for the hypocalcemic response observed in TPTX animals cannot be ascertained from the present results. Particularly, one cannot rule out an additional PTH-independent action on bone resorption as suggested from the data presented in a recent preliminary communication (15) .
Finally, our results confirm that WR-272 1 induces a parallel decrement in the plasma levels of both divalent cations, Ca and Mg. Furthermore, they show that complete prevention of hypomagnesemia has no influence on the magnitude of the hypocalcemic response. Therefore, it appears very unlikely that decrease in extracellular Ca concentration is due to alteration in magnesemia. Preliminary data from our laboratory rather suggest that WR-272 1 exerts a PTH-independent inhibitory activity on the tubular Mg reabsorption (16) .
In conclusion, the present experimental study supports the suggestion that WR-2721 inhibits PTH secretion, and moreover, demonstrates that this drug exerts an inhibitory PTH-independent effect on the tubular reabsorption of Ca. An additional effect on bone resorption cannot be excluded. Therefore WR-2721 could be very useful in the management of clinical situations where the plasma level of PTH and Ca have to be rapidly reduced. We have recently reported on the case of a patient with parathyroid carcinoma (17) . Administration of a single dose of WR-272 1 led to a rapid reduction in the plasma level of PTH and Ca which was reversible within 24 h. This observation suggests that WR-2721 can also interfere with autonomous aberrant PTH secretion. Further studies should investigate whether the drug could be effective in the long-term treatment of hyperparathyroidism or hypercalcemia ofother origins.
